Abstract
B cell lineage acute lymphoblastic leukemia is the most common leukemia occurring in children and young adults and is the leading cause of cancer related deaths. The 5 year overall survival outcome in children with B-ALL has improved significantly in the last few decades. In the past, the discovery of various genetic alterations and targeted therapy have played a major role in decreasing disease-related deaths. In addition, numerous advances in the pathogenesis of B-ALL have been found which have provided better understanding of the genes involved in disease biology with respect to diagnostic and prognostic implications. Present review will summarize current understanding of risk stratification, genetic factors including cytogenetics in diagnosis and prognosis of B-ALL.
Similar content being viewed by others
References
Mullighan CG (2012) The molecular genetic makeup of acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2012:389–396
Inaba H, Greaves M, Mullighan CG (2013) Acute lymphoblastic leukaemia. The Lancet 381(9881):1943–1955
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390
Hunger SP, Mullighan CG (2015) Acute lymphoblastic leukemia in children. N Engl J Med 373(16):1541–1552
Secker-Walker LM, Lawler SD, Hardisty RM (1978) Prognostic implications of chromosomal findings in acute lymphoblastic leukaemia at diagnosis. Br Med J 2(6151):1529–1530
Dastugue N, Suciu S, Plat G, Speleman F, Cave H, Girard S et al (2013) Hyperdiploidy with 58–66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. Blood 121(13):2415–2423
Paulsson K, Johansson B (2009) High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosom Cancer 48(8):637–660
Carroll WL (2013) Safety in numbers: hyperdiploidy and prognosis. Blood 121(13):2374–2376
Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ (2010) A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood 115(2):206–214
Nachman JB, Heerema NA, Sather H, Camitta B, Forestier E, Harrison CJ et al (2007) Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110(4):1112–1115
Raimondi SC, Zhou Y, Mathew S, Shurtleff SA, Sandlund JT, Rivera GK et al (2003) Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer 98(12):2715–2722
Harrison CJ, Moorman AV, Broadfield ZJ, Cheung KL, Harris RL, Reza Jalali G et al (2004) Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol 125(5):552–559
Safavi S, Paulsson K (2017) Near-haploid and low-hypodiploid acute lymphoblastic leukemia: two distinct subtypes with consistently poor prognosis. Blood 129(4):420–423
Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L et al (2013) The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 45(3):242–252
Pui CH, Williams DL, Raimondi SC, Rivera GK, Look AT, Dodge RK et al (1987) Hypodiploidy is associated with a poor prognosis in childhood acute lymphoblastic leukemia. Blood 70(1):247–253
Nowell PC (1960) A minute chromosome in human chronic granulocytic leukemia. Science 142:1497
Eisenberg A, Silver R, Soper L, Arlin Z, Coleman M, Bernhardt B et al (1988) The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. Leukemia 2(10):642–647
Reckel S, Hantschel O (2017) Bcr-Abl: one kinase, two isoforms, two diseases. Oncotarget [Internet]. 8(45). Available from: https://www.oncotarget.com/fulltext/20874. Cited 8 Jun 2018
Junmei Z, Fengkuan Y, Yongping S, Baijun F, Yuzhang L, Lina L et al (2015) Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib. SpringerPlus [Internet]. 4(1). Available from: http://www.springerplus.com/content/4/1/170. Cited 8 Jun 2018
Gupta SK, Bakhshi S, Kumar L, Kamal VK, Kumar R (2017) Gene copy number alteration profile and its clinical correlation in B cell acute lymphoblastic leukemia. Leukemia Lymphoma 58(2):333–342
Singh M, Bhatia P, Trehan A, Varma N, Sachdeva MS, Bansal D et al (2018) High frequency of intermediate and poor risk copy number abnormalities in pediatric cohort of B-ALL correlate with high MRD post induction. Leuk Res 66:79–84
Siddaiahgari S, Awaghad M, Latha M (2015) Clinical, immunophenotype and cytogenetic profile of acute lymphoblastic leukemia in children at tertiary health care centre in India. Muller J Med Sci Res 6(2):112
Pui C-H, Robison LL, Look AT (2008) Acute lymphoblastic leukaemia. The Lancet 371(9617):1030–1043
Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, Masera G et al (1999) Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 354(9189):1499–1503
Pui C-H, Carroll WL, Meshinchi S, Arceci RJ (2011) Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 29(5):551–565
Amare PSK, Jain H, Kabre S, Deshpande Y, Pawar P, Banavali S et al (2016) Cytogenetic Profile in 7209 Indian patients with de novo acute leukemia: a single centre study from India. J. Cancer Ther 07(07):530–544
Ziemin-van der Poel S, McCabe NR, Gill HJ, Espinosa R, Patel Y, Harden A et al (1991) Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci USA 88(23):10735–10739
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405
Safavi M, Safaei A, Lotfi M (2018) A rare variant of t(17;19) in a case of Philadelphia positive adult acute lymphoblastic leukemia presenting with disseminated intravascular coagulation. Blood Res 53(1):92
On behalf of the Ponte di Legno International Workshop in Childhood Acute Lymphoblastic Leukemia, Harrison CJ, Moorman AV, Schwab C, Carroll AJ, Raetz EA et al (2014) An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 28(5):1015–1021
Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE et al (2010) Prognostic effect of chromosomal abnormalities in childhood B cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 11(5):429–438
Moorman AV, Richards SM, Robinson HM, Strefford JC, Gibson BES, Kinsey SE et al (2007) Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 109(6):2327–2330
Rand V, Parker H, Russell LJ, Schwab C, Ensor H, Irving J et al (2011) Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B cell precursor acute lymphoblastic leukemia. Blood 117(25):6848–6855
Robinson HM, Harrison CJ, Moorman AV, Chudoba I, Strefford JC (2007) Intrachromosomal amplification of chromosome 21 (iAMP21) may arise from a breakage–fusion–bridge cycle. Genes Chromosom Cancer 46(4):318–326
Li Y, Schwab C, Ryan SL, Papaemmanuil E, Robinson HM, Jacobs P et al (2014) Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature 508(7494):98–102
Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang Y-L, Pei D et al (2014) Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 371(11):1005–1015
Tran TH, Loh ML (2016) Ph-like acute lymphoblastic leukemia. Hematology 2016(1):561–566
Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen I-M et al (2017) High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol 35(4):394–401
Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H et al (2017) Targetable kinase gene fusions in high risk B-ALL: a study from the Children’s Oncology Group. Blood. blood-2016–12–758979.
Kastner P, Dupuis A, Gaub M-P, Herbrecht R, Lutz P, Chan S (2013) Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia. Am J Blood Res 3(1):1–13
Tijchon E, Havinga J, van Leeuwen FN, Scheijen B (2013) B-lineage transcription factors and cooperating gene lesions required for leukemia development. Leukemia 27(3):541–552
van der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, te Kronnie G, Harrison CJ et al (2014) IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 123(11):1691–1698
Mi J-Q, Wang X, Yao Y, Lu H-J, Jiang X-X, Zhou J-F et al (2012) Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases. Leukemia 26(7):1507–1516
Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S et al (2009) Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell’Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 114(10):2159–2167
Yeoh AEJ, Lu Y, Chin WHN, Chiew EKH, Lim EH, Li Z et al (2018) Intensifying treatment of childhood B lymphoblastic leukemia with IKZF1 deletion reduces relapse and improves overall survival: results of Malaysia–Singapore ALL 2010 study. J Clin Oncol 36(26):2726–2735
Harvey RC, Mullighan CG, Chen I-M, Wharton W, Mikhail FM, Carroll AJ et al (2010) Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 115(26):5312–5321
Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ et al (2009) Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B cell precursor acute lymphoblastic leukemia. Blood 114(13):2688–2698
Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ et al (2010) Functional screening identifies CRLF2 in precursor B cell acute lymphoblastic leukemia. Proc Natl Acad Sci 107(1):252–257
Usvasalo A, Savola S, Räty R, Vettenranta K, Harila-Saari A, Koistinen P et al (2008) CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study. Leuk Res 32(8):1228–1235
Mirebeau D, Acquaviva C, Suciu S, Bertin R, Dastugue N, Robert A et al (2006) The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica 91(7):881–885
Bertin R, Acquaviva C, Mirebeau D, Guidal-Giroux C, Vilmer E, Cavé H (2003) CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia: CDKN2A, CDKN2B, and MTAP Dosage in Leukemia. Genes Chromosom Cancer 37(1):44–57
Heerema NA, Sather HN, Sensel MG, Liu-Mares W, Lange BJ, Bostrom BC et al (1999) Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood 94(5):1537–1544
Kasner MT, Wilde L, Keiffer G, Palmisiano ND, Calabretta B (2019) A phase I trial of palbociclib in combination with dexamethasone in relapsed or refractory adult B cell acute lymphoblastic leukemia (ALL). J Clin Oncol 37(15):TPS7065
Zhou Y, You MJ, Young KH, Lin P, Lu G, Medeiros LJ et al (2012) Advances in the molecular pathobiology of B lymphoblastic leukemia. Hum Pathol 43(9):1347–1362
Cobaleda C, Schebesta A, Delogu A, Busslinger M (2007) Pax5: the guardian of B cell identity and function. Nat Immunol 8(5):463–470
Öfverholm I, Tran AN, Heyman M, Zachariadis V, Nordenskjöld M, Nordgren A et al (2013) Impact of IKZF1 deletions and PAX5 amplifications in pediatric B cell precursor ALL treated according to NOPHO protocols. Leukemia 27(9):1936–1939
Sherr CJ, McCormick F (2002) The RB and p53 pathways in cancer. Cancer Cell 2(2):103–112
Studniak E, Maloney E, Ociepa T, Urasiński T, Skonieczka K, Haus O et al (2013) Allelic loss of selected tumor suppressor genes in acute lymphoblastic leukemia in children. Pol J Pathol 2:121–128
Waanders E, Scheijen B, van der Meer LT, van Reijmersdal SV, van Emst L, Kroeze Y et al (2012) The origin and nature of tightly clustered BTG1 deletions in precursor B cell acute lymphoblastic leukemia support a model of multiclonal evolution. PLoS Genet 8(2):e1002533
Schwab C, Ryan SL, Chilton L, Elliott A, Murray J, Richardson S et al (2016) EBF1-PDGFRB fusion in pediatric B cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood 127(18):2214–2218
Nunez R (2001) DNA measurement and cell cycle analysis by flow cytometry. Curr Issues Mol Biol 3(3):67–70
Parihar M, Singh MK, Islam R, Saha D, Mishra DK, Saha V et al (2018) A triple-probe FISH screening strategy for risk-stratified therapy of acute lymphoblastic leukaemia in low-resource settings. Pediatr Blood Cancer 65(12):e27366
Campana D (2009) Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol 46(1):100–106
Brüggemann M, Kotrova M (2017) Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Adv 1(25):2456–2466
Terwilliger T, Abdul-Hay M (2017) Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 7(6):e577
Mathisen MS, O’Brien S, Thomas D, Cortes J, Kantarjian H, Ravandi F (2011) Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep 6(3):187–194
Leoni V, Biondi A (2015) Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. Haematologica 100(3):295–299
Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA et al (2013) MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia. Leukemia 27(1):113–117
Chiarini F, Lonetti A, Evangelisti C, Buontempo F, Orsini E, Evangelisti C et al (2016) Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: from biology to therapeutic targeting. Biochim Biophys Acta (BBA) Mol Cell Res 1863(3):449–463
Ling Y, Xie Q, Zhang Z, Zhang H (2018) Protein kinase inhibitors for acute leukemia. Biomarker Research [Internet]. 6(1). Available from: https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-018-0123-1. Cited 17 Dec 2019
Lionel D, Christophe L, Marc A, Jean-Luc C (2006) Oral mucositis induced by anticancer treatments: physiopathology and treatments. Ther Clin Risk Manag 2(2):159–168
Du X-L, Chen Q (2013) Recent advancements of bortezomib in acute lymphocytic leukemia treatment. Acta Haematol 129(4):207–214
Takahashi K, Inukai T, Imamura T, Yano M, Tomoyasu C, Lucas DM et al (2017) Anti-leukemic activity of bortezomib and carfilzomib on B cell precursor ALL cell lines. PLoS ONE 12(12):e0188680
Degryse S, Cools J (2015) JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia. Journal of Hematology & Oncology [Internet]. 8(1). Available from: https://www.jhoonline.org/content/8/1/91. Cited 17 Jun 2018
Harrison C, Vannucchi AM (2012) Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Ther Adv Hematol 3(6):341–354
Novel HD, Leukemia A-B (2011) Hematology 2011(1):243–249
Levato L, Molica S (2018) Rituximab in the management of acute lymphoblastic leukemia. Expert Opin Biol Ther 18(2):221–226
Raetz EA, Cairo MS, Borowitz MJ, Lu X, Devidas M, Reid JM et al (2015) Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children’s Oncology Group (COG) study ADVL04P2: re-Induction With Epratuzumab in Relapsed ALL. Pediatr Blood Cancer 62(7):1171–1175
Hathaway L, Sen JM, Keng M (2018) Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date. Patient Relat Outcome Measures 9:329–337
Mummery A, Narendran A, Lee K-Y (2011) Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia. Curr Cancer Drug Targets 11(7):882–893
Masetti R, Serravalle S, Biagi C, Pession A (2011) The role of HDACs inhibitors in childhood and adolescence acute leukemias. J Biomed Biotechnol 2011:1–9
Jing B, Jin J, Xiang R, Liu M, Yang L, Tong Y, et al (2018) Vorinostat and quinacrine have synergistic effects in T cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition. Cell Death Disease [Internet]. 9(6). Available from: https://www.nature.com/articles/s41419-018-0679-6. Cited 17 Dec 2019
Ravandi F, Gandhi V (2006) Novel purine nucleoside analogues for T cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs 15(12):1601–1613
Robak P, Robak T (2013) Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev 39(8):851–861
Bonate PL, Arthaud L, Cantrell WR, Stephenson K, Secrist JA, Weitman S (2006) Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 5(10):855–863
Kadia TM, Gandhi V (2017) Nelarabine in the treatment of pediatric and adult patients with T cell acute lymphoblastic leukemia and lymphoma. Expert Rev Hematol 10(1):1–8
Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L (2013) γ-Secretase inhibitors and modulators. Biochim Biophys Acta (BBA) Biomembr 1828(12):2898–2907
Greene LM, Nathwani SM, Zisterer DM (2016) Inhibition of γ-secretase activity synergistically enhances tumour necrosis factor-related apoptosis-inducing ligand induced apoptosis in T cell acute lymphoblastic leukemia cells via upregulation of death receptor 5. Oncol Lett 12(4):2900–2905
Evangelisti C, Evangelisti C, Chiarini F, Lonetti A, Buontempo F, Bressanin D et al (2014) Therapeutic potential of targeting mTOR in T cell acute lymphoblastic leukemia (Review). Int J Oncol 45(3):909–918
Acknowledgements
The name of the department(s) and institution(s) to which the work should be attributed: Department of Laboratory sciences and Molecular medicine, Army Hospital (R&R), New Delhi, India.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Agarwal, M., Seth, R. & Chatterjee, T. Recent Advances in Molecular Diagnosis and Prognosis of Childhood B Cell Lineage Acute Lymphoblastic Leukemia (B-ALL). Indian J Hematol Blood Transfus 37, 10–20 (2021). https://doi.org/10.1007/s12288-020-01295-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-020-01295-8